Research
Dr. Akshay Jain has actively participated as the local site primary investigator for the following Clinical Phase III/ IV studies using novel medications/devices for treatment of diabetes, obesity, cardiovascular disease and elevated cholesterol.
- PIONEER REAL: Real world outcome study with oral semaglutide (National PI)
- PREFER CA: Real world outcome study with flash glucose monitoring in basal insulin
- SPOT FIRST: Real world outcome with flash glucose monitoring prior to specialist appointment
- SURE: Real world outcome study with Semaglutide
- REALISE-DM: Real world outcome on switching from liraglutide/dulaglutide to semaglutide
- GLITTER: Real world outcome using retrospective flash glucose monitoring
- DECLARE- TIMI: MACE outcome study with Dapagliflozin
- CAMELLIA: MACE outcome study with Lorcaserin
- SERTUS: Active comparator efficacy study with Ertugliflozin
- CANNON: Albuminuria study with Canagliflozin in DM-1
- REWIND: MACE outcome study with Dulaglutide
- SPIRE 1 &2: Cardiovascular outcome study with Bococizumab
- LEXICON: Insulin dose outcome study with Sotagliflozin in DM-1
- EASE-2: Safety and Tolerability study with Empagliflozin in DM-1
- CANCARE: Prospective registry database study with Canagliflozin
- ONSET 8: Randomized controlled trial with insulin Degludec and Faster acting Insulin Aspart in DM-1
- GOAL RCT: Randomized controlled trial comparing effect of colesevelam versus ezetimibe as add-on to HMG CoA Reductase inhibitor therapy in DM-2